Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYMAKER-U01 Substudy 3 in PD-(L)1 Refractory NSCLC
2023-506934-56-00Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 7
01
Overview
Phase 2 trial of pembrolizumab, rolistobart, boserolimab and mk-4830 in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Merck & Co. Primary endpoint: Objective Response Rate (ORR) According to RECIST 1.1. Started Jan 2024; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-506934-56-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506934-56-00.